Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Testing the Re-Engineered Hospital Discharge

This study has been completed.
Information provided by:
Boston University Identifier:
First received: November 10, 2005
Last updated: January 14, 2016
Last verified: April 2009
Results First Received: February 10, 2009  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Single Blind (Outcomes Assessor);   Primary Purpose: Prevention
Condition: All
Intervention: Behavioral: Re-Engineered Discharge

  Participant Flow

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Re-engineered Hospital Discharge Participants received the "Re-Engineered Hospital Discharge", a set of 11 discrete, mutually reinforcing components provided by a Discharge Advocate and re-enforced by a telephone call 2-4 days after discharge by a clinical pharmacist.
Standard Hospital Discharge Participants received the routine, standard hospital discharge.
Total Total of all reporting groups

Baseline Measures
    Re-engineered Hospital Discharge     Standard Hospital Discharge     Total  
Number of Participants  
[units: participants]
  373     376     749  
[units: participants]
<=18 years     0     0     0  
Between 18 and 65 years     312     314     626  
>=65 years     61     62     123  
[units: years]
Mean (Standard Deviation)
  50.1  (15.1)     49.6  (15.3)     49.9  (15.2)  
[units: participants]
Female     178     199     377  
Male     195     177     372  
Region of Enrollment  
[units: participants]
United States     373     376     749  

  Outcome Measures

1.  Primary:   Total Number of Rehospitalizations (Emergency Department Visits Plus Hospital Admissions) in the 30 Days After Discharge.   [ Time Frame: 30 days after discharge ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information